Results 11 to 20 of about 169,062 (205)

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Headache, 2021
To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.
J. Ailani, R. Burch, M. Robbins
semanticscholar   +1 more source

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

The Journal of Headache and Pain, 2022
Background A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world
S. Sacco, F. Amin, M. Ashina, L. Bendtsen, C. Deligianni, R. Gil-Gouveia, Z. Katsarava, A. Maassenvandenbrink, P. Martelletti, D. Mitsikostas, R. Ornello, U. Reuter, M. Sanchez-del-Rio, A. Sinclair, G. Terwindt, D. Uluduz, J. Versijpt, C. Lampl   +17 more
semanticscholar   +1 more source

Migraine: A Review on Its History, Global Epidemiology, Risk Factors, and Comorbidities

Frontiers in Neurology, 2022
Migraine affects more than one billion individuals each year across the world, and is one of the most common neurologic disorders, with a high prevalence and morbidity, especially among young adults and females.
P. Amiri, S. Kazeminasab, S. A. Nejadghaderi, R. Mohammadinasab, H. Pourfathi, Mostafa Araj-khodaei, M. Sullman, Ali-Asghar Kolahi, S. Safiri   +8 more
semanticscholar   +1 more source

Diagnosis and management of migraine in ten steps

Nature Reviews Neurology, 2021
Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated.
Anna K. Eigenbrodt, H. Ashina, Sabrina Khan, H. Diener, D. Mitsikostas, A. Sinclair, P. Pozo‐Rosich, P. Martelletti, A. Ducros, M. Lanteri-Minet, M. Braschinsky, M. del Río, Oved Daniel, A. Özge, A. Mammadbayli, M. Arons, K. Skorobogatykh, V. Romanenko, G. Terwindt, K. Paemeleire, S. Sacco, U. Reuter, C. Lampl, H. Schytz, Z. Katsarava, T. Steiner, M. Ashina   +26 more
semanticscholar   +1 more source

Migraine: from pathophysiology to treatment

Journal of Neurology, 2023
Migraine is an extremely disabling, common neurological disorder characterized by a complex neurobiology, involving a series of central and peripheral nervous system areas and networks.
F. Puledda, E. Silva, Kanokrat Suwanlaong, P. Goadsby   +3 more
semanticscholar   +1 more source

Genetics of migraine: where are we now?

The Journal of Headache and Pain, 2023
Migraine is a complex brain disorder explained by the interaction of genetic and environmental factors. In monogenic migraines, including familial hemiplegic migraine and migraine with aura associated with hereditary small-vessel disorders, the ...
L. Grangeon, K. S. Lange, M. Waliszewska-Prosół, D. Onan, Karol Marschollek, Wietse A. Wiels, Petr Mikulenka, F. Farham, C. Gollion, A. Ducros   +9 more
semanticscholar   +1 more source

Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles

Nature Genetics, 2021
Migraine affects over a billion individuals worldwide but its genetic underpinning remains largely unknown. Here, we performed a genome-wide association study of 102,084 migraine cases and 771,257 controls and identified 123 loci, of which 86 are ...
Heidi Hautakangas, B. Winsvold, S. Ruotsalainen, G. Bjornsdottir, A. V. Harder, Lisette J. A. Kogelman, Laurent F. Thomas, R. Noordam, C. Benner, P. Gormley, V. Artto, K. Banasik, A. Bjornsdottir, D. Boomsma, B. Brumpton, K. Burgdorf, J. Buring, M. A. Chalmer, I. de Boer, M. Dichgans, C. Erikstrup, M. Färkkilä, Maiken Elvestad Garbrielsen, M. Ghanbari, K. Hagen, Paavo Häppölä, J. Hottenga, M. Hrafnsdottir, K. Hveem, M. B. Johnsen, M. Kähönen, E. Kristoffersen, T. Kurth, T. Lehtimäki, Lannie Lighart, S. Magnusson, R. Malik, O. Pedersen, N. Pelzer, B. Penninx, C. Ran, P. Ridker, F. Rosendaal, Gudrun R. Sigurdardottir, A. Skogholt, O. Sveinsson, T. Thorgeirsson, H. Ullum, L. Vijfhuizen, E. Widén, K. W. van Dijk, Irene Arn M. J. M. de Boer van den Maagdenberg, I. de Boer, A. M. van den Maagdenberg, A. Aromaa, A. C. Belin, T. Freilinger, M. Ikram, M. Järvelin, O. Raitakari, G. Terwindt, M. Kallela, M. Wessman, Jes Olesen, D. Chasman, D. Nyholt, H. Stefánsson, K. Stefánsson, T. Hansen, S. Ripatti, J. Zwart, A. Palotie, M. Pirinen   +72 more
semanticscholar   +1 more source

Regular Practice of Autogenic Training Reduces Migraine Frequency and Is Associated With Brain Activity Changes in Response to Fearful Visual Stimuli

Frontiers in Behavioral Neuroscience, 2022
Several factors can contribute to the development and chronification of migraines, including stress, which is undoubtedly a major trigger. Beyond pharmacotherapy, other treatment methods also exist, including behavioral techniques aiming at reducing ...
Dóra Dobos, Dóra Dobos, Edina Szabó, Edina Szabó, Edina Szabó, Dániel Baksa, Dániel Baksa, Kinga Gecse, Kinga Gecse, Natália Kocsel, Natália Kocsel, Dorottya Pap, Terézia Zsombók, Lajos R. Kozák, Gyöngyi Kökönyei, Gyöngyi Kökönyei, Gyöngyi Kökönyei, Gabriella Juhász, Gabriella Juhász, Gabriella Juhász, Gabriella Juhász   +20 more
doaj   +1 more source

Atogepant for the Preventive Treatment of Migraine.

New England Journal of Medicine, 2021
BACKGROUND Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist that is being investigated for the preventive treatment of migraine. METHODS In a phase 3, double-blind trial, we randomly assigned adults with 4 to 14
J. Ailani, R. Lipton, P. Goadsby, Hua Guo, R. Miceli, L. Severt, M. Finnegan, Joel M. Trugman   +7 more
semanticscholar   +1 more source

The Migraine Stigma Kaleidoscope View

Neurology and Therapy, 2023
The stigma of migraine, despite an impressive body of data on the epidemiological of migraine and the associated disability, burden and cost of migraine to patients, has not been fully evaluated as an important factor in the chronicization of the disease
Elena Gross, Elena Ruiz de la Torre, Paolo Martelletti   +2 more
doaj   +1 more source